麻豆约拍

A new vaccine has been shown to be highly effective in large-scale trials in the UK. The vaccine, from the US maker Novavax is reporting nearly 90% efficacy and most importantly, is also the first to show that it works against the new UK strain and - though to a lesser degree - against the South African variant of the virus, in trials there.

The UK has secured 60 million doses of the jab, which will be made in Stockton-on-Tees.

For more, we spoke to the Novavax's chief commercial and business office John Trizzino.
"We're seeing this triple mutant strain in South Africa and then a variation of that in the UK. 90% of South Africans who were tested in this trial that were confirmed with the virus were with this triple mutant and so we believe this is having an effect."

(Photo: A doctor lifts a vial with a coronavirus vaccine at Novavax labs in Maryland, United States. Credit: AFP)